Evaluation of activity and toxicity of combining clioquinol with ciclopirox and terbinafine in alternative models of dermatophytosis.


Journal

Mycoses
ISSN: 1439-0507
Titre abrégé: Mycoses
Pays: Germany
ID NLM: 8805008

Informations de publication

Date de publication:
Jul 2021
Historique:
revised: 18 03 2021
received: 31 12 2020
accepted: 23 03 2021
pubmed: 28 3 2021
medline: 7 10 2021
entrez: 27 3 2021
Statut: ppublish

Résumé

Dermatophytosis is a superficial fungal infection that affects humans and is very common in small animals. The treatment using the most commonly used antifungals is failing, and new therapeutic alternatives are required to combat the resistance of these fungal infections. Previous studies by the group have shown that clioquinol is an important therapeutic alternative in the treatment of dermatophytosis. The object was to conduct studies of antidermatophytic activity and the irritant potential from the double and triple combinations of clioquinol, terbinafine and ciclopirox in ex vivo and in vivo alternative models. To evaluate the irritant potential of antifungal combinations, the alternative HET-CAM method (chicken egg test chorioallantoic membrane) was used. Ex vivo models were used to assess the effectiveness of antifungal combinations, using pig hooves and veterinary fur. Any possible tissue damage was to assess through in histopathology of swine ears. HET-CAM results showed that all combinations can be classified as non-irritating, corroborated by the results of the histopathological evaluation of the pig's ear skin. Only the double combinations managed to remove 100% of the colony-forming units (CFU) formed on the pig's hooves. The clioquinol + terbinafine combination and the triple combination were more effective than clioquinol + ciclopirox in eradicating the preformed biofilm in fur of veterinary origin. These results show the potential of formulations of clioquinol in combination with antifungals for use in humans and in the veterinary field to combat dermatophytosis, as an important alternative therapy, for use in the near future.

Identifiants

pubmed: 33772895
doi: 10.1111/myc.13276
doi:

Substances chimiques

Antifungal Agents 0
Drug Combinations 0
Ciclopirox 19W019ZDRJ
Clioquinol 7BHQ856EJ5
Terbinafine G7RIW8S0XP

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

727-733

Informations de copyright

© 2021 Wiley-VCH GmbH.

Références

Tartor YH, Abo Hashem ME, Enany S. Towards a rapid identification and a novel proteomic analysis for dermatophytes from human and animal dermatophytosis. Mycoses. 2019;62(12):1116-1126.
da Cunha MM, Capote-Bonato F, Capoci IRG, et al. Epidemiological investigation and molecular typing of dermatophytosis caused by Microsporum canis in dogs and cats. Prev Vet Med. 2019;167:39-45.
Moriello KA, Coyner K, Paterson S, Mignon B. Diagnosis and treatment of dermatophytosis in dogs and cats.: clinical consensus guidelines of the world association for veterinary dermatology. Vet Dermatol. 2017;28(3):266-268.
Chermette R, Ferreiro L, Guillot J. Dermatophytoses in Animals. Mycopathologia. 2008;166(5-6):385-405.
Dalla Lana AJ, Pippi B, Carvalho AR, et al. In Vitro additive effect on griseofulvin and terbinafine combinations against multidrug-resistant dermatophytes. Braz J Pharm Sci. 2018;54(2):e17149.
Pires CAA, da Cruz NFS, Lobato AM, Sousa PO, Carneiro FR, Mendes AMD. Clinical, epidemiological, and therapeutic profile of dermatophytosis. An Bras Dermatol. 2014;89(2):259-264.
White TC, Findley K, Dawson TL Jr, et al. Fungi on the skin: dermatophytes and Malassezia. Cold Spring Harb Perspect Med. 2014;4(8):a019802.
Moriello KA. In vitro efficacy of shampoos containing miconazole, ketoconazole, climbazole or accelerated hydrogen peroxide against microsporum canis and trichophyton species. J Feline Med Surg. 2017;19(4):370-374.
Fuentefria A, Pippi B, Dalla Lana D, Donato K, de Andrade S. Antifungals discovery: an insight into new strategies to combat antifungal resistance. Lett Appl Microbiol. 2018;66:2-13.
Nofal A, Fawzy MM, El-Hawary EE. Successful treatment of resistant onychomycosis with voriconazole in a liver transplant patient. Dermatol Ther. 2020;33:e14014.
Mao X, Schimmer AD. The toxicology of clioquinol. Toxicol Lett. 2008;182(1-3):1-6.
Pippi B, Lopes W, Reginatto P, et al. (2018) “New insights into the mechanism of antifungal action of 8-hydroxyquinolines”. Saudi Pharm J. 2019;27(1):41-48.
Pippi B, Reginatto P, da Machado GRM, et al. Evaluation of 8-hydroxyquinoline derivatives as hits for antifungal drug design. Med Mycol. 2017;55(7):763-773.
da Costa B, Pippi B, Andrzejewski Kaminski TF, Andrade SF, Fuentefria AM. In vitro antidermatophytic synergism of double and triple combination of clioquinol with ciclopirox and terbinafine. Mycoses. 2020;63:1-9.
Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous fungi, Approved Standard 2nd edn. CLSI Document M38-A2. Wayne, PA: Clinical Laboratory Standards Institute; 2008.
Oliveira AGL, Silva RS, Alves EM, Presgrave RF, Presgrave OAF, Delgado IF. Chorioallantoic membrane assays (HET-CAM and CAM-TBS): alternative tests for performing toxicological evaluation of products with low potential for ocular irritation. Revista do Instituto Adolfo Lutz. 2012;71(1):153-159.
Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVMA). The Hen's Egg Test-Chorioallantoic Membrane (HET-CAM) Test Method. Research Triangle Park: National Toxicology Program; 2010.
Brasil. Ministerio da agricultura. Instrução Normativa nº 3/2000. Aprova Regulamento Técnico de Métodos de Insensibilização para Abate Humanitário de Animais de Açougue; 2013.
Quatrin PM, Kaminski TFA, Berlitz SJ, Guerreiro ICK, Canto RFS, Fuentefria AM. Ex vivo nail infection as an effective preclinical method for screening of new topical antifungals. J Mycol Med. 2020;30(2):100938.
Lossi L, Merighi A. The use of Ex vivo rodent platforms in neuroscience translational research with attention to the 3Rs philosophy. Front Vet Sci. 2018;5:1-14.
Rosso JQDEL. Onychomycosis and the emergence of newer agents. Clin Aesthet. 2014;7(7):10-18.
Lipner SR. Pharmacotherapy for Onychomycosis new and emerging treatments.pdf. Exp Opin Pharmacother. 2019;20(6):725-735.
Santos DA, Hamdan JS. In vitro antifungal oral drug and drug-combination activity against Onychomycosis causative dermatophytes. Med Mycol. 2006;44(4):357-362.
Baran R, Sigurgeirsson B, de Berker D, et al. A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of Onychomycosis with matrix invol. Br J Dermatol. 2007;157(1):149-157.
Evans E. Drug synergies and the potential for combination therapy in Onychomycosis. Br J Dermatol. 2003;149(65):11-13.
Perrins N, Bond R. Synergistic inhibition of the growth in vitro of Microsporum Canis by miconazole and chlorhexidine. Vet Dermatol. 2003;14(2):99-102.
Nam H-S, Kim T-Y, Han S-H, Changbaig H. Evaluation of therapeutic efficacy of medical shampoo containing terbinafine hydrochloride and chlorhexidine in dogs with dermatophytosis complicated with bacterial infection. J Biomed Res. 2013;14:154-159.
Danielli LJ, Pippi B, Duarte JA, et al. (2018) “Antifungal mechanism of action of Schinus lentiscifolius Marchand essential oil and its synergistic effect in vitro with terbinafine and ciclopirox against dermatophytes”. J Pharm Pharmacol. 2018;70(9):1216-1227.
Gupta AK, Paquet M, Simpson FC. Therapies for the treatment of onychomycosis. Clin Dermatol. 2013;31:544-554.
Gupta M, Agrawal U, Vyas SP. Nanocarrier-based topical drug delivery for the treatment of skin diseases. Exp Opin Drug Deliv. 2012;9(7):783-804.
Beck MH, Wilkinson SM. A distinctive irritant contact reaction to vioform (Clioquinol). Contact Dermatitis. 1994;31:55.
Kero M, Hannuksekla M, Sothman A. Primary irritant dermatitis from topical clioquinol. Contact Dermatitis. 1979;5:115-117.
Morris SD, Rycroft RJ, White IR, Wakelin SH, McFadden JP. Contact dermatitis and allergy comparative frequency of patch test reactions to topical antibiotics. Br J Dermatol. 2002;146:1047-1051.
Mussani F, Poon D, Skotnicki-grant S. Systemic contact dermatitis to topical clioquinol/hydrocortisone combination cream. Dermatitits. 2013;24(4):196-197.
Foti C, Diaferio A, Bonamonte D. Allergic contact dermatitis from ciclopirox olamine. Australas J Dermatol. 2001;42(2):145.
Bhari N, Sahni K, Dev T, Sharma VK. Symmetrical drug-related intertriginous and flexural erythema (baboon syndrome) induced by simultaneous exposure to oral and topical terbinafine. Int J Dermatol. 2017;56(8):e168-e170.

Auteurs

Bárbara da Costa (B)

Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.

Bruna Pippi (B)

Departamento de Microbiologia e Parasitologia, Universidade Federal de Santa Maria, Santa Maria, Brazil.

Simone Jacobus Berlitz (SJ)

Programa de Pós-Graduação em Nanotecnologia Farmacêutica, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.

Anderson Ramos Carvalho (AR)

Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.

Mario Lettieri Teixeira (ML)

Laboratório de Farmacologia, Instituto Federal Catarinense, Campus Concórdia, Concórdia, Brazil.

Irene Clemes Külkamp-Guerreiro (IC)

Programa de Pós-Graduação em Nanotecnologia Farmacêutica, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.

Saulo F Andrade (SF)

Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.

Alexandre Meneghello Fuentefria (AM)

Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH